Latest LTRN ETF News Today | Earnings, Events & Price Alerts

LTRN News

Growth Prospects for the EGFR-NSCLC Market Analyzed

4d agoNewsfilter

Lantern Pharma CEO to Present at Glioblastoma Summit

6d agoBusinesswire

New to The Street Highlights Blockchain and Oncology Innovations in Episode #710

Dec 27 2025Yahoo Finance

Lantern Pharma Announces Encouraging Phase 1a Results for LP-184 in Advanced Solid Tumors

Dec 03 2025NASDAQ.COM

Lantern Pharma Showcases LP-284 Clinical Findings at 25th LL&M Congress, Emphasizing Full Response in DLBCL Patient with Limited Treatment Options and Its Promise for Advanced B-Cell Cancers.

Oct 28 2025Newsfilter

Lantern Pharma to Showcase at ThinkEquity Conference in New York City on October 30, 2025

Oct 24 2025Newsfilter

Lantern Pharma Reports Positive Safety and Initial Efficacy Results for Cancer Drug in Phase 1 Trial

Sep 16 2025Yahoo Finance

Lantern Pharma Reports Successful Phase 1a Study of LP-184 in Advanced Solid Tumors, Achieving All Primary Endpoints

Sep 16 2025NASDAQ.COM

IBN Unveils New Episode of The BioMedWire Podcast with Panna Sharma, CEO of Lantern Pharma Inc. (LTRN), a Biotech Innovator Targeting Challenging and Rare Cancers

Sep 10 2025Newsfilter

IBN Unveils New Episode of The BioMedWire Podcast with Panna Sharma, CEO of Lantern Pharma Inc. (LTRN), a Biotech Innovator Targeting Challenging and Rare Cancers

Sep 10 2025Globenewswire

Lantern Pharma Concludes Type C Meeting with FDA, Clarifying Regulatory Path for Pediatric CNS Cancer Study

Sep 03 2025Newsfilter

Lantern Pharma Narrows Loss in Q2

Aug 13 2025NASDAQ.COM

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

Aug 13 2025Newsfilter

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Aug 06 2025Newsfilter

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

Aug 04 2025Newsfilter

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Jul 31 2025Newsfilter

LTRN

LTRN

LTRN News

Growth Prospects for the EGFR-NSCLC Market Analyzed

Lantern Pharma CEO to Present at Glioblastoma Summit

New to The Street Highlights Blockchain and Oncology Innovations in Episode #710

Lantern Pharma Announces Encouraging Phase 1a Results for LP-184 in Advanced Solid Tumors

Lantern Pharma Showcases LP-284 Clinical Findings at 25th LL&M Congress, Emphasizing Full Response in DLBCL Patient with Limited Treatment Options and Its Promise for Advanced B-Cell Cancers.

Lantern Pharma to Showcase at ThinkEquity Conference in New York City on October 30, 2025

Lantern Pharma Reports Positive Safety and Initial Efficacy Results for Cancer Drug in Phase 1 Trial

Lantern Pharma Reports Successful Phase 1a Study of LP-184 in Advanced Solid Tumors, Achieving All Primary Endpoints

IBN Unveils New Episode of The BioMedWire Podcast with Panna Sharma, CEO of Lantern Pharma Inc. (LTRN), a Biotech Innovator Targeting Challenging and Rare Cancers

IBN Unveils New Episode of The BioMedWire Podcast with Panna Sharma, CEO of Lantern Pharma Inc. (LTRN), a Biotech Innovator Targeting Challenging and Rare Cancers

Lantern Pharma Concludes Type C Meeting with FDA, Clarifying Regulatory Path for Pediatric CNS Cancer Study

Lantern Pharma Narrows Loss in Q2

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

Lantern Pharma&#39;s Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial